ImmunityBio's Anktiva Gains New Approvals and Momentum
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 20 2026
0mins
Should l Buy IBRX?
Source: stocktwits
- Therapy Expansion: ImmunityBio's Anktiva has been included in the NCCN guidelines as a recommended option for patients with papillary bladder cancer unresponsive to BCG, thereby expanding the potential patient population, although formal FDA approval is still pending.
- Clinical Data Support: Recent clinical data indicates that 58.2% of patients remained cancer-free at 12 months, while over 80% avoided bladder removal surgery, highlighting the therapy's efficacy and significance in treatment.
- International Market Push: Anktiva has received approvals in markets like Saudi Arabia and plans to expand distribution across the Middle East and North Africa, showcasing ImmunityBio's strategic positioning and market expansion capabilities globally.
- Stock Market Reaction: IBRX shares have risen over 5% this week, breaking a two-week losing streak, reflecting positive market sentiment following Anktiva's inclusion in Macau's drug list and the NCCN guideline expansion.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.380
Low
5.00
Averages
7.33
High
9.00
Current: 7.380
Low
5.00
Averages
7.33
High
9.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ImmunityBio's Bladder Cancer Drug Trial Confirms Statistical Power
- Trial Statistical Power Confirmed: The Independent Data Monitoring Committee (IDMC) confirmed that ImmunityBio's pivotal randomized trial for Anktiva is adequately powered with the current 366 participants, ensuring the study's effectiveness in detecting clinically meaningful differences in complete response rates.
- Clinical Trial Progress: The QUILT-2.005 trial evaluates Anktiva in combination with Bacillus Calmette-Guérin (BCG) for patients with non-muscle invasive bladder cancer, showing promising results from earlier phases with prolonged complete remission durations, enhancing confidence for subsequent research.
- FDA Regulatory Dynamics: The U.S. FDA reviewed direct-to-consumer advertising for Anktiva, deeming it misleading and unsupported in claims of curing or preventing cancer, highlighting the importance of compliance in promotional materials.
- Analyst Ratings and Targets: ImmunityBio's stock carries a Buy rating with an average price target of $12.57, while D. Boral Capital maintains a target of $23.00, reflecting market confidence in the company's future potential.
See More
ImmunityBio Under Investigation for Possible Securities Law Violations
- FDA Warning Letter: On March 24, 2026, ImmunityBio received a warning letter from the FDA indicating that Executive Chairman Patrick Soon-Shiong made false claims on a podcast about the company's lead biologic product, Anktiva, stating it could 'cure and even prevent all cancer,' leading the FDA to deem the advertising misleading.
- Stock Price Plunge: Following the FDA's warning, ImmunityBio's stock price fell by $1.98, or 21.12%, closing at $7.42 per share, which directly impacted investors and raised concerns about the company's compliance with federal regulations.
- Legal Consultation Opportunity: The Law Offices of Howard G. Smith announced an investigation into ImmunityBio, encouraging affected investors to reach out to explore potential claims for recovering losses, highlighting the importance of legal support for investor rights.
- Investor Rights Protection: This investigation aims to assist impacted investors in understanding their legal rights and may provide avenues for loss recovery, emphasizing the necessity for investors to seek legal assistance when companies face compliance issues.
See More
ImmunityBio Faces Class Action Lawsuit Over Anktiva Claims
- Class Action Initiation: ImmunityBio, Inc. (NASDAQ: IBRX) is facing a class action lawsuit due to alleged false statements regarding its lead product Anktiva, with a deadline of May 26, 2026, for investors to seek lead plaintiff status for losses incurred between January 19, 2026, and March 24, 2026.
- FDA Warning Letter Impact: A warning letter from the FDA dated March 13, 2026, highlighted misleading advertising practices regarding Anktiva, resulting in a 21% drop in stock price following the news, indicating significant market concerns over the company's compliance and credibility.
- False Advertising Allegations: The lawsuit claims that ImmunityBio failed to disclose that Anktiva's long-term efficacy was unproven and falsely marketed it as a cancer vaccine, which not only harmed investor interests but could also adversely affect the company's future market performance.
- Law Firm Background: Robbins Geller Rudman & Dowd LLP, a leading firm in securities fraud and shareholder rights litigation, recovered over $916 million for investors in 2025, showcasing its strong capabilities and influence in handling similar cases.
See More
IBRX Stock Poised for Breakout Quarter: Anktiva Launches Phase 2 Long COVID Trial Amid European Expansion Plans
Phase 2 Long COVID Study Launch: The company has initiated a Phase 2 study to assess the effectiveness of Anktiva in improving recovery from long COVID by restoring immune cells, with plans to enroll about 20 participants and complete the study by October.
Expansion Beyond Cancer: Anktiva's platform has expanded its applications beyond cancer treatments to include severe pneumonia, sepsis, and acute respiratory distress syndrome, indicating a broader potential for immune activation therapies.
Stock Performance and Market Sentiment: Shares of ImmunityBio (IBRX) have surged over 270% this year, significantly outperforming the S&P Biotech ETF, reflecting positive market sentiment and renewed interest in the company's therapies.
Regulatory Progress and Future Plans: The therapy has been added to approved drug lists for bladder cancer and is being positioned as a recommended option for patients who do not respond to standard therapies, with ongoing efforts to expand its use in various diseases.
See More
ImmunityBio Faces Class Action Lawsuit
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against ImmunityBio, seeking damages for investors who purchased the company's securities between January 19, 2026, and March 24, 2026, reflecting strong investor response to potential fraud allegations.
- False Statement Allegations: The complaint alleges that ImmunityBio's executive Soon-Shion materially overstated Anktiva's capabilities, resulting in the company's statements about its business, operations, and prospects being deemed materially false and misleading, which could significantly impact the company's reputation and stock price.
- Investor Participation Opportunity: Affected investors are encouraged to apply to be lead plaintiffs by May 26, 2026, indicating that the legal process offers a chance for investors to recover losses, potentially attracting more attention from investors to the case.
- No-Risk Legal Services: Bronstein, Gewirtz & Grossman, LLC offers legal services on a contingency fee basis, charging only if they successfully recover funds, which lowers the barrier for investor participation in the lawsuit and enhances confidence in legal action.
See More
Class Action Filed Against ImmunityBio Securities
- Class Action Initiation: Rosen Law Firm has filed a class action lawsuit on behalf of ImmunityBio securities purchasers from January 19 to March 24, 2026, alleging that the company made false or misleading statements during this period, resulting in investor losses.
- Compensation Mechanism: Investors participating in the lawsuit may be entitled to compensation without any out-of-pocket fees, indicating a risk-free legal avenue for investors to seek recovery of their losses.
- Law Firm Background: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its strength and experience in handling such cases.
- Lawsuit Details: The lawsuit claims that ImmunityBio's executive Patrick Soon-Shiong materially overstated Anktiva's capabilities, leading to materially false statements about the company's business prospects, which resulted in investor damages when the truth emerged.
See More
ImmunityBio's Bladder Cancer Drug Trial Confirms Statistical Power
- Trial Statistical Power Confirmed: The Independent Data Monitoring Committee (IDMC) confirmed that ImmunityBio's pivotal randomized trial for Anktiva is adequately powered with the current 366 participants, ensuring the study's effectiveness in detecting clinically meaningful differences in complete response rates.
- Clinical Trial Progress: The QUILT-2.005 trial evaluates Anktiva in combination with Bacillus Calmette-Guérin (BCG) for patients with non-muscle invasive bladder cancer, showing promising results from earlier phases with prolonged complete remission durations, enhancing confidence for subsequent research.
- FDA Regulatory Dynamics: The U.S. FDA reviewed direct-to-consumer advertising for Anktiva, deeming it misleading and unsupported in claims of curing or preventing cancer, highlighting the importance of compliance in promotional materials.
- Analyst Ratings and Targets: ImmunityBio's stock carries a Buy rating with an average price target of $12.57, while D. Boral Capital maintains a target of $23.00, reflecting market confidence in the company's future potential.
See More
ImmunityBio Under Investigation for Possible Securities Law Violations
- FDA Warning Letter: On March 24, 2026, ImmunityBio received a warning letter from the FDA indicating that Executive Chairman Patrick Soon-Shiong made false claims on a podcast about the company's lead biologic product, Anktiva, stating it could 'cure and even prevent all cancer,' leading the FDA to deem the advertising misleading.
- Stock Price Plunge: Following the FDA's warning, ImmunityBio's stock price fell by $1.98, or 21.12%, closing at $7.42 per share, which directly impacted investors and raised concerns about the company's compliance with federal regulations.
- Legal Consultation Opportunity: The Law Offices of Howard G. Smith announced an investigation into ImmunityBio, encouraging affected investors to reach out to explore potential claims for recovering losses, highlighting the importance of legal support for investor rights.
- Investor Rights Protection: This investigation aims to assist impacted investors in understanding their legal rights and may provide avenues for loss recovery, emphasizing the necessity for investors to seek legal assistance when companies face compliance issues.
See More
ImmunityBio Faces Class Action Lawsuit Over Anktiva Claims
- Class Action Initiation: ImmunityBio, Inc. (NASDAQ: IBRX) is facing a class action lawsuit due to alleged false statements regarding its lead product Anktiva, with a deadline of May 26, 2026, for investors to seek lead plaintiff status for losses incurred between January 19, 2026, and March 24, 2026.
- FDA Warning Letter Impact: A warning letter from the FDA dated March 13, 2026, highlighted misleading advertising practices regarding Anktiva, resulting in a 21% drop in stock price following the news, indicating significant market concerns over the company's compliance and credibility.
- False Advertising Allegations: The lawsuit claims that ImmunityBio failed to disclose that Anktiva's long-term efficacy was unproven and falsely marketed it as a cancer vaccine, which not only harmed investor interests but could also adversely affect the company's future market performance.
- Law Firm Background: Robbins Geller Rudman & Dowd LLP, a leading firm in securities fraud and shareholder rights litigation, recovered over $916 million for investors in 2025, showcasing its strong capabilities and influence in handling similar cases.
See More
IBRX Stock Poised for Breakout Quarter: Anktiva Launches Phase 2 Long COVID Trial Amid European Expansion Plans
Phase 2 Long COVID Study Launch: The company has initiated a Phase 2 study to assess the effectiveness of Anktiva in improving recovery from long COVID by restoring immune cells, with plans to enroll about 20 participants and complete the study by October.
Expansion Beyond Cancer: Anktiva's platform has expanded its applications beyond cancer treatments to include severe pneumonia, sepsis, and acute respiratory distress syndrome, indicating a broader potential for immune activation therapies.
Stock Performance and Market Sentiment: Shares of ImmunityBio (IBRX) have surged over 270% this year, significantly outperforming the S&P Biotech ETF, reflecting positive market sentiment and renewed interest in the company's therapies.
Regulatory Progress and Future Plans: The therapy has been added to approved drug lists for bladder cancer and is being positioned as a recommended option for patients who do not respond to standard therapies, with ongoing efforts to expand its use in various diseases.
See More
ImmunityBio Faces Class Action Lawsuit
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against ImmunityBio, seeking damages for investors who purchased the company's securities between January 19, 2026, and March 24, 2026, reflecting strong investor response to potential fraud allegations.
- False Statement Allegations: The complaint alleges that ImmunityBio's executive Soon-Shion materially overstated Anktiva's capabilities, resulting in the company's statements about its business, operations, and prospects being deemed materially false and misleading, which could significantly impact the company's reputation and stock price.
- Investor Participation Opportunity: Affected investors are encouraged to apply to be lead plaintiffs by May 26, 2026, indicating that the legal process offers a chance for investors to recover losses, potentially attracting more attention from investors to the case.
- No-Risk Legal Services: Bronstein, Gewirtz & Grossman, LLC offers legal services on a contingency fee basis, charging only if they successfully recover funds, which lowers the barrier for investor participation in the lawsuit and enhances confidence in legal action.
See More
Class Action Filed Against ImmunityBio Securities
- Class Action Initiation: Rosen Law Firm has filed a class action lawsuit on behalf of ImmunityBio securities purchasers from January 19 to March 24, 2026, alleging that the company made false or misleading statements during this period, resulting in investor losses.
- Compensation Mechanism: Investors participating in the lawsuit may be entitled to compensation without any out-of-pocket fees, indicating a risk-free legal avenue for investors to seek recovery of their losses.
- Law Firm Background: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its strength and experience in handling such cases.
- Lawsuit Details: The lawsuit claims that ImmunityBio's executive Patrick Soon-Shiong materially overstated Anktiva's capabilities, leading to materially false statements about the company's business prospects, which resulted in investor damages when the truth emerged.
See More
